{
    "nctId": "NCT01434303",
    "briefTitle": "Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only",
    "officialTitle": "Phase I and Phase I Trastuzumab Cohort Study of Entinostat, Lapatinib and Trastuzumab in Patients With HER2-Positive Metastatic Breast Cancer in Whom Trastuzumab Has Failed",
    "overallStatus": "COMPLETED",
    "conditions": "HER2/Neu Positive, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 37,
    "primaryOutcomeMeasure": "RP2D for entinostat in combination with lapatinib ditosylate defined as the highest dose level in which 6 patients have been treated with at most 1 patient experiencing dose limiting toxicity",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients have histological confirmation of invasive breast carcinoma\n* Patients have locally recurrent or distant relapsed metastatic disease\n* Patients have positive HER2 expression by immunohistochemistry (IHC) (3+) or fluorescence in situ hybridization (FISH) testing (\\> 2.0 ratio)\n* Patients are able to swallow and retain oral medication (i.e., no uncontrolled vomiting, inability to swallow, or diagnosis of chronic malabsorption)\n* Patients have Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Patients must have received prior trastuzumab for \\> 2 month period before disease recurrence or recurrence or progression while on trastuzumab-based therapy\n* Patients have ability and willingness to sign written informed consent\n* Female patients of childbearing potential (a female not free from menses \\> 2 years or not surgically sterilized) must be willing to use an adequate barrier method of contraception to prevent pregnancy or agree to abstain from heterosexual activity throughout the study; male patients who are able to father children must use an adequate barrier method of contraception\n* Female patients of childbearing potential must have negative serum pregnancy test within 14 days of starting protocol therapy\n* Patients with brain metastasis have no signs of progressive disease 4 months after the completion of brain metastasis treatment (radiation therapy, surgery, etc.) do not require anticonvulsants or corticosteroids, and have been off such drugs for at least 7 days\n* Both men and women and members of all races and ethnic groups are eligible for this trial\n\nExclusion Criteria:\n\n* Patients are receiving concurrent anti-cancer therapy (chemotherapy, immunotherapy, biological therapy and hormonal therapy) while taking study medication\n* Serum bilirubin \\>= 1.5 x upper limit of normal (ULN)\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\>= 3 x ULN (with or without liver metastasis \\[mets\\])\n* Absolute neutrophil count (ANC) \\< 1.5\n* Hemoglobin =\\< 9\n* Platelet =\\< 140,000\n* Patients have an active infection and require intravenous (IV) or oral antibiotics\n* Cardiac arrhythmia requiring maintenance medication\n* History of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug\n* Patients have a concurrent disease or condition that would make them inappropriate for study participation, or any serious medical disorder that would interfere with patients' safety\n* Serum creatinine \\> 2.0 mg/dL",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}